Tech Company Financing Transactions
Avitide Funding Round
Avitide, based in Lebanon, scored investment from NeoMed Management, Borealis Ventures and OrbiMed.
Transaction Overview
Company Name
Announced On
8/6/2015
Transaction Type
Venture Equity
Amount
Unknown
Round
Series C
Investors
NeoMed Management (Lead Investor) (Claudio Nessi)
Borealis Ventures (Philip Ferneau)
Polaris Partners (Terry McGuire)
SV Health Investors (Michael Ross)
Proceeds Purpose
The proceeds will accelerate commercialization of Avitide's on-demand affinity purification platform, with a focus on biopharmaceutical drug products that include an array of molecules such as proteins, enzymes, antibody-based therapeutics, recombinant vaccines, gene therapies and biosimilars. The financing is expected to take the company to profitability within the next two years.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
16 Cavendish Ct.
Lebanon, NH 03766
USA
Lebanon, NH 03766
USA
Phone
Website
Email Address
Overview
Avitide develops customized biopharmaceutical affinity purification products with an industry-leading discovery and development service time.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Tillman Gerngross
Chief Executive Officer
Kevin Isett
Chief Financial Officer
Scott Kennedy
Chief Scientific Officer
Warren Kett
VP - Bus. Development
Daniel Freymeyer
VP - Engineering
Karol Lacki
VP - General Counsel
Kimberly Cornwell
VP - Manufacturing
Grant Espie
Browse more venture capital transactions:
Prev: 8/6/2015: Razzor venture capital transaction
Next: 8/6/2015: SnobSwap venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs